Galapagos says GSK starting trials of its new drug
BRUSSELS Feb 5 (Reuters) - Belgian biotech company Galapagos said on Tuesday that its partner GlaxoSmithKline (GSK) planned to start Phase II studies into a drug candidate to treat two auto-immune disorders.
Galapagos said in a statement that GSK would launch the studies for compound GSK2586184 in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
Galapagos is eligible to receive 34 million euros in additional milestones plus up to double-digit percentage royalties on global sales. It is the second selective JAK1 molecule discovered by Galapagos to enter Phase 2 studies.
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- U.S. Secret Service investigates after man jumps White House fence, reaches doors
- French jets strike in Iraq, expanding U.S.-led campaign against Islamic State |
- Alice, steampunk and a false name: enigma of an American jailed in North Korea
- North Korea says imprisoned American tried to become 'second Snowden'